12 December 2017 - Today on Universal Health Coverage Day, The International Union Against Tuberculosis and Lung Disease (The Union) and the International Council of Nurses (ICN) have launched updated guidance for health care workers who are involved in detecting and caring for patients with tuberculosis (TB).

On World Human Rights Day, The Union restates the need for greater political action in order to achieve the Sustainable Development Goals (SDGs) for health, including ending the deadly epidemic of tuberculosis (TB) by 2030 and to ensure that all people can fulfil their human right to health.

The International Journal of Tuberculosis and Lung Disease (IJTLD) is the official publication of the International Union Against Tuberculosis and Lung Disease (The Union).

World Antibiotic Awareness Week will take place next week from 13-19 November, shining a spotlight on the growing crisis of antimicrobial resistance (AMR). The first descriptions of infectious diseases becoming resistant to the antimicrobial treatments available were in 1948 and were for drugs used to treat tuberculosis (TB).

In 2015, The Union appointed Nomampondo – Noma - Barnabas as its Civil Society Liaison Officer, to build bridges with members of the movement and also inform The Union’s understanding of the issues internally.

The Union announced a series of commitments to combat antimicrobial resistance (AMR) at a conference, in Berlin on 12 and 13 October 2017, organised by Wellcome in partnership with the UK, Ghanaian and Thai governments and the UN Foundation.

The International Journal of Tuberculosis and Lung Disease (IJTLD) is the official publication of the International Union Against Tuberculosis and Lung Disease (The Union).

The International Journal of Tuberculosis and Lung Disease (IJTLD) is the official publication of the International Union Against Tuberculosis and Lung Disease (The Union).

Guadalajara, Mexico, 13 October 2017 - Preliminary results - released today at the 48^th Union Conference on Lung Health - from Stage 1 of the STREAM randomised clinical trial show that the nine-month treatment regimen being tested achieved favourable outcomes in almost 80 percent of those treated.